Using a novel compact intraoperative imaging device, Synchronized Infra-Red Imaging System (SIRIS), and a targeted imaging agent, Tumor Paint BLZ-100, researchers aim to increase survival and reduce neurological deficits in patients with gliomas. In experimental models of brain, lung and breast tumors, SIRIS detects BLZ-100, which preferentially binds to a variety of human malignancies but shows little or no binding to normal human tissue. When stimulated by a laser in the near-infrared part of the spectrum, BLZ-100 emits a glow SIRIS captures.
Preliminary research shows SIRIS, along with BLZ-100, can delineate brain tumors in real time and assist surgeons in near-complete removal. Because SIRIS penetrates deep into tissue, BLZ-100 captures tumor metastasis.